TYK Medicines, Inc (HKG:2410)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
9.97
-0.15 (-1.48%)
Apr 29, 2026, 4:08 PM HKT
-63.48%
Market Cap 3.84B
Revenue (ttm) n/a
Net Income (ttm) -333.58M
Shares Out 384.67M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,068,000
Average Volume 2,486,550
Open 10.18
Previous Close 10.12
Day's Range 9.96 - 10.18
52-Week Range 9.81 - 34.35
Beta n/a
RSI 36.26
Earnings Date Jun 1, 2026

About TYK Medicines

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including b... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 173
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2410
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.